Atazanavir/Selected QT Prolonging Agents
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both of your medicines may affect your heart's rhythm.
What might happen:
Taking two medicines that can affect your heart rhythm may increase your risk of an irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g doctor or pharmacist) know that you are taking these medications together. Let your doctor know right away if you notice an irregular heartbeat or have dizziness or fainting episodes. Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Saphris (asenapine) US prescribing information. Schering Corporation October, 2011.
2.Cipro (ciprofloxacin hydrochloride) US prescribing information. Bayer Corporation August, 2013.
3.Celexa (citalopram hydrobromide) US prescribing information. Forest Laboratories Inc. December, 2012.
4.Clozaril (clozapine tablets) US prescribing information. Novartis Pharmaceuticals Corporation March, 2013.
5.Ciproxin (ciprofloxacin hydrochloride) UK summary of product characteristics. Bayer plc April 13, 2010.
6.Xalkori (crizotinib) US prescribing information. Pfizer Inc. November, 2013.
7.Mathivanan M. Dear Canadian Healthcare Professional: Subject: Association of domperidone maleate with serious ventricular arrhythmias and sudden cardiac death. Teva Canada Limited March 2, 2012.
8.Halaven (eribulin mesylate) US prescribing information. Eisai, Inc. August, 2013.
9.Potiga (ezogabine) US Prescribing Information. Valeant Pharmaceuticals September, 2013.
10.Foradil Aerolizer (formoterol fumarate) US prescribing information. Schering Corporation September, 2012.
11.Symbicort Turbuhaler (budesonide-eformoterol fumarate dihydrate) Australian prescribing information. AstraZeneca Pty Ltd April 30, 2004.
12.Ablavar (gadofosveset trisodium) US prescribing information. Lantheus Medical Imaging, Inc. August, 2013.
13.Primovist (gadoxetate disodium) Australian prescribing information. Schering-Plough Corporation November 1, 2005.
14.Primovist (gadoxetic acid) UK summary of product characteristics. Bayer plc May 1, 2008.
15.Procoralan (ivabradine hydrochloride) summary of product characteristics. Servier December, 2005.
16.Serentil (mesoridazine besylate) US prescribing information. Novartis Pharmaceuticals Corporation August, 2000.
17.Kon P. Dear UK Healthcare Professional: Direct Healthcare Professional Communication on ondansetron (Zofran and generics) and dose-dependent QT interval prolongation - new dose restriction for intravenous (IV) use. GlaxoSmithKline UK Ltd August 5, 2012.
18.Zofran (ondansetron) US prescribing information. GlaxoSmithKline December, 2013.
19.USFood and Drug Administration. FDA Drug Safety Communication: Abnormal heart rhythms may be associated with use of Zofran (ondansetron). available at: http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm September 15, 2011.
20.Invega (paliperidone) US prescribing information. Janssen Pharmaceuticals, Inc. April, 2011.
21.Invega Sustenna (paliperidone palmitate) US prescribing information. Janssen Pharmaceuticals, Inc. August, 2012.
22.Aloxi (polonosetron hydrochloride) US prescribing information. MGI Pharma September, 2007.
23.Signifor (pasireotide diasparate) US prescribing information. Novartis Pharmaceuticals Corporation December, 2012.
24.Qualaquin (quinine sulfate) US prescribing information. AR Scientific, Inc. April, 2013.
25.Edurant (rilpivirine) US prescribing information. Tibotec Pharmaceuticals June, 2013.
26.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.
27.Nexavar (sorafenib) US prescribing information. Bayer Pharmaceuticals Corporation November, 2013.
28.Vibativ (telavancin) US prescribing information. Astellas Pharma US, Inc. September, 2009.
29.Xenazine (tetrabenazine) US prescribing information. Ovation Pharmaceuticals, Inc. September, 2008.
30.Caprelsa (vandetanib) US prescribing information. AstraZeneca Pharmaceuticals LP July, 2013.
31.Zelboraf (vemurafenib) US Prescribing Information. Hoffman-La Roche July, 2013.
32.Javlor (vinflunine ditartrate) UK Summary of Product Characteristics. Pierre Fabre Limited September 21, 2009.
33.Clopixol (zuclopenthixol acetate) UK summary of product characteristics. Lundbeck House October 24, 2008.
34.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.